Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma

Abstract Survival rates for patients with high‐risk large B‐cell lymphoma (LBCL), particularly those with biological risk factors, remain inadequate. We conducted a biomarker‐driven phase II trial involving 123 high‐risk patients aged 18–64 with LBCL. Based on their biological risk profiles, patient...

Full description

Bibliographic Details
Published in:HemaSphere
Main Authors: Sirpa Leppä, Leo Meriranta, Maare Arffman, Judit Jørgensen, Marja‐Liisa Karjalainen‐Lindsberg, Klaus Beiske, Mette Pedersen, Kristina Drott, Annika Pasanen, Kristiina Karihtala, Susanna Mannisto, Bente Wold, Marianne Brodtkorb, Unn‐Merete Fagerli, Thomas Stauffer Larsen, Lars Munksgaard, Kaisa Sunela, Øystein Fluge, Sirkku Jyrkkiö, Peter Brown, Harald Holte
Format: Article
Language:English
Published: Wiley 2025-05-01
Online Access:https://doi.org/10.1002/hem3.70139

Internet

https://doi.org/10.1002/hem3.70139

Similar Items